Promoted Content
Promoted Content

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): IPP-201101

            Therapeutic Area: Immunology Product Name: Lupuzor

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 20, 2020

            Details:

            As part of the Type ‘A’ Meeting, Avion has asked the FDA for guidance on the Key aspects of the study design, clinical end points and approval process for Lupuzor™; and Consideration by the FDA for a conditional approval of Lupuzor™, whilst the Phase 3 trial is underway.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Grass MATA MPL

            Therapeutic Area: Immunology Product Name: Grass MATA MPL

            Highest Development Status: Phase III Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable October 26, 2020

            Details:

            Allergy Therapeutics announces start of key exploratory field study in advance of pivotal Phase III Grass trial;Breakthrough study design to deliver for the first time cutting edge scientific concepts in the Allergy field to optimize SCIT trial results.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tree MATA MPL

            Therapeutic Area: Immunology Product Name: Tree MATA MPL

            Highest Development Status: Phase III Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 09, 2020

            Details:

            Technical issues in the study made it difficult to reconstruct the primary endpoint data and the PEI agreed that B301 cannot be considered for assessment of clinical efficacy and a new pivotal Phase III study will be conducted within the therapy allergens ordinance time frame.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Rigerimod

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Phase III Product Type: Large molecule

            Partner/Sponsor/Collaborator: Avion Pharmaceuticals

            Deal Size: $100.0 million Upfront Cash: Undisclosed

            Deal Type: Agreement February 06, 2020

            Details:

            Avion and ImmuPharma to meet with the FDA in Q1 2020 to discuss guidance on a new optimised international Phase III trial protocol.